IMR Press / EJGO / Volume 39 / Issue 2 / DOI: 10.12892/ejgo3716.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Is human papilloma virus DNA and cytokeratin 19 useful as micrometastatic markers in cervical cancer patients only with intermediate risk factors?
Show Less
1 Department of Pathology, Kyungpook National University Medical Center, Daegu, South Korea
2 Department of Obstetrics and Gynecology, Kyungpook National University Medical Center, Daegu, South Korea
Eur. J. Gynaecol. Oncol. 2018, 39(2), 210–215; https://doi.org/10.12892/ejgo3716.2018
Published: 10 April 2018
Abstract

Purpose: This study was designed to evaluate high risk human papilloma virus (HPV) DNA and cytokeratin 19 (CK19) as micrometastatic markers in cervical cancer patients only with intermediate risk factors. Materials and Methods: Polymerase chain reaction (PCR) for high-risk HPV DNA and immunohistochemistry for CK19 were performed in 335 lymph nodes from 67 patients. Results: HPV DNA and CK19 were detected in 23.5% and 2.7% of lymph nodes, respectively. HPV DNA was detected in 31 patients (46.3%), while CK19 was expressed in five patients (7.4%). The five-year disease-free and overall survival rates were 90.5% in the CK19- or HPV DNA-positive group and 76.8% in the negative group. There was no correlation between disease-free survival and CK19 or HPV DNA positivity. Conclusion: For the cervical cancer with intermediate risk factors, the presence of high-risk HPV DNA in lymph nodes is not useful as a micrometastatic marker, while CK19 expression requires further study.
Keywords
Cervical cancer
Intermediate risk factor
Cytokeratin 19
Human papilloma virus
Share
Back to top